USMA Regional Medical Scientific Director – GI Immunology, South Texas (Remote)
- – Merck & Co., Inc. has released a statement addressing forward-looking statements and clarifying its responsibilities regarding updates to information presented on its website.
- The statement, referencing the United States Private Securities Litigation Reform Act of 1995, acknowledges that the company's website contains forward-looking statements.
- According to the company, no guarantees are made regarding pipeline products, including assurances of regulatory approvals or commercial success.Merck cautions that actual results may differ materially from those...
Merck & Co. Issues Forward-Looking Statement and Disclaimer
Table of Contents
KENILWORTH, N.J. – Merck & Co., Inc. has released a statement addressing forward-looking statements and clarifying its responsibilities regarding updates to information presented on its website.
Forward-Looking Statement
The statement, referencing the United States Private Securities Litigation Reform Act of 1995, acknowledges that the company’s website contains forward-looking statements. These statements are based on current beliefs and expectations of Merck’s management and are subject to risks and uncertainties.
According to the company, no guarantees are made regarding pipeline products, including assurances of regulatory approvals or commercial success.Merck cautions that actual results may differ materially from those projected in forward-looking statements if underlying assumptions prove inaccurate or if risks or uncertainties materialize.
Potential risks and uncertainties cited by the company include, but are not limited to:
- General industry conditions and competition
- General economic factors, including interest rate and currency exchange rate fluctuations
- The impact of pharmaceutical industry regulation and healthcare legislation in the U.S. and internationally
- Global trends toward healthcare cost containment
- Technological advances, new products, and patents attained by competitors
- Challenges inherent in new product development, including obtaining regulatory approval
- The company’s ability to accurately predict future market conditions
- Manufacturing difficulties or delays
- Financial instability of international economies and sovereign risk
- Dependence on the effectiveness of the company’s patents and other protections for innovative products
- Exposure to litigation, including patent litigation, and/or regulatory actions
No Obligation to Update
Merck & Co.explicitly states it undertakes no obligation to publicly update any forward-looking statement, whether due to new information, future events, or other factors. the company directs readers to its 2015 Annual Report on Form 10-K and other filings with the Securities and Exchange Commission (SEC) for additional factors that could cause results to differ materially from forward-looking statements. These documents are available on the SEC’s website.
Information Currency
The company emphasizes that information on its website was current as of the date presented. Merck assumes no duty to update this information to reflect subsequent developments. Investors are cautioned not to rely on the information as current or accurate after the initial presentation date.
Merck & Co.Forward-Looking Statements: A Guide for investors
Here’s a breakdown of Merck & Co.’s forward-looking statements and disclaimers, presented in a clear, question-and-answer format. This shoudl help you,as an investor or interested party,understand the key takeaways from their statement.
What is a Forward-Looking Statement?
Q: What is a forward-looking statement, as mentioned in Merck’s statement?
A: According to Merck & Co. (Merck) referencing the United States Private securities Litigation reform Act of 1995,a forward-looking statement is a projection of future events,subject to risks and uncertainties. These statements are based on current beliefs and expectations of Merck’s management.
Q: What are forward-looking statements based on?
A: They are based on current beliefs and expectations of Merck’s management.
Risks and Uncertainties
Q: What types of uncertainties does Merck identify as potential risks to their forward-looking statements?
A: Merck identifies a broad range of potential risks and uncertainties, including:
General industry conditions and competition.
General economic factors, including interest rate and currency exchange rate fluctuations.
The impact of pharmaceutical industry regulation and healthcare legislation in the U.S. and internationally.
Global trends toward healthcare cost containment.
Technological advances, new products, and patents attained by competitors.
Challenges inherent in new product progress,including obtaining regulatory approval.
The company’s ability to accurately predict future market conditions.
Manufacturing difficulties or delays.
Financial instability of international economies and sovereign risk.
Dependence on the effectiveness of the company’s patents and other protections for innovative products.
Exposure to litigation, including patent litigation, and/or regulatory actions.
Q: Why are these risks critically important for investors?
A: As these risks can cause actual results to differ considerably from what Merck initially projects in their forward-looking statements.
No Obligation to Update
Q: Does Merck have to update its forward-looking statements?
A: No. Merck explicitly states that it undertakes no obligation to publicly update any forward-looking statement, irrespective of new details, future events, or other factors.
Q: Why doesn’t Merck update its forward-looking statements?
A: Because they are based on the company’s viewpoint at the time of publication. The company directs readers to its 2015 Annual Report for more details.
Information Currency & Investor Responsibility
Q: How current is the information on Merck’s website?
A: According to the statement, information on the website was current as of the date presented. Merck assumes no duty to update the information.
Q: As an investor, what should I keep in mind about the information’s currency?
A: Investors are cautioned not to rely on the information as current or accurate after the initial presentation date. You should always refer to the most up-to-date filings with the SEC for the latest information.
Key Takeaways for Investors
Q: What are the key takeaways for investors from Merck’s statement?
A: Here’s a quick summary:
Forward-looking statements are not guarantees. They are based on current beliefs, and actual results can vary.
Be aware of numerous potential risks. Review the identified categories of risks and uncertainties.
Don’t expect updates. Merck is not obligated to update forward-looking statements.
Always check official filings. Refer to Merck’s Annual Report on Form 10-K and other SEC filings for complete and the most up-to-date information.
Consider the date. Information on the website might not be recent.
Comparing Risks and Uncertainties
Q: Are the risks and Uncertainties the same for any pharmaceutical company?
A: No, risks vary between companies. Here’s a rough comparison based on the source content:
| Risk Category t| Merck & Co. t| Other Pharmaceutial Companies (general assumption) t|
| :——————————————- t| :——————————————————— t| :——————————————————— t|
| Industry Conditions & Competition t| Yes t| Yes t|
| Economic Factors t| Yes (interest rates, currency fluctuations) t| Yes t|
| Regulation & Legislation t| Yes (U.S. & International) t| Yes t|
| Healthcare Cost Containment t| Yes t| Yes t|
| Technological Advances & Patents t| Yes (competitors) t| Yes t|
| New Product Development t| Yes (Regulatory Approval) t| Yes (Regulatory Approval) t|
| Future Market Condition Prediction ability t| Yes t| Yes t|
| Manufacturing Challenges t| Yes (Difficulties or Delays) t| Yes t|
| International Economic and Financial Instability | Yes (Sovereign Risk) t| Yes t|
| Patent Effectiveness t| Yes t| Yes t|
| Litigation & Regulatory Actions t| Yes (Patent Litigation) t| Yes t|
Note: This table is constructed based on the limited information provided and shouldn’t be used for investment advice.